Depressive symptoms are common in schizophrenia and can worsen outcomes and increase suicide risk. Lurasidone ( latuda ) is an atypical antipsychotic agent indicated for the treatment of schizophrenia and for the treatment of major depressive episodes associated with bipolar I disorder.
A post hoc analysis has evaluated the effect of Lurasidone on depressive symptoms in patients with schizophrenia.
Patient-level data were pooled from 4 similarly designed, double-blind, placebo-controlled, 6-week registration studies of Lurasidone ( 40-160 mg/d ) in adult patients with an acute exacerbation of schizophrenia.
Changes in depressive symptoms, measured by the Montgomery-Åsberg Depression Rating Scale ( MADRS ), were analyzed for the overall sample and for subgroups of patients stratified by baseline MADRS scores.
MADRS assessments at baseline and endpoint ( day 42 or last observation carried forward [ LOCF ] ) were available for 1330 patients.
Patients receiving Lurasidone experienced significantly greater decreases in MADRS score ( -2.8, least-squares [ LS ] mean change, LOCF ) compared with patients receiving placebo ( -1.4, P less than 0.001, effect size 0.24 ).
Analysis of change in MADRS score ( LOCF ) by baseline symptom severity ( MADRS score of greater than or equal to 12, greater than or equal to 14, greater than or equal to 16, greater than or equal to 18 ) showed significantly greater improvement for Lurasidone-treated patients across all severity groups; effect sizes ranged from 0.25 to 0.34.
Among patients with a baseline MADRS score of greater than or equal to 12, depressive symptom remission ( defined as MADRS score less than 10 at LOCF endpoint ) was attained by 45.0% of Lurasidone-treated patients and 36.3% of patients receiving placebo ( P less than 0.05 ).
In a pooled analysis of short-term, placebo-controlled studies, Lurasidone significantly improved depressive symptoms in patients with schizophrenia. ( Xagena )
Nasrallah HA et al, CNS Spectr 2014:1-8